Thyroid Cancer

Endostatin curbs follicular thyroid carcinoma in animal models

Published in Cancer Weekly, September 24th, 2002

by Sonia Nichols, senior medical writer - Scientists have learned that endostatin can curve the growth of human follicular thyroid carcinoma (FTC) in animal models.

Endostatin is a natural inhibitor of angiogenesis, or neovascularization. Medical investigators from China, in conjunction with colleagues at the University of Pittsburgh School of Medicine in Pennsylvania, have determined recombinant or retroviral-mediated delivery of endostatin limits the proliferation of thyroid cancers implanted into nude mice.

Initially, Caisheng Ye and colleagues treated FTC-implanted mice with recombinant protein.

"Our results demonstrated that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-09-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry